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See Article, pages 1127–1134In patients with chronic hepatitis B (CHB) and cirrhosis, the
5-year probability for hepatic decompensation if untreated is
around 5–20% with a 5 year survival ranging between 14% and
35% [1]. The development of oral nucleotide and nucleoside
analogues (NUCs) for treatment of chronic hepatitis B (CHB) has
revolutionized the prognosis of this large population of patients
worldwide. For more than a decade, such agents are now
routinely used for treatment of decompensated CHB. Indeed,
early studies conducted in Taiwan, provided already evidence
that lamivudine (LAM) prevents fatality in decompensated CHB,
reducing mortality from 25% (in historical controls) to only
4.2%, provided treatment is started early enough before bilirubin
levels rise above 20 mg/dl [2]. The introduction of more potent
NUCs with a better resistance proﬁle than LAM and an excellent
safety record such as Entecavir (ETV), Tenofovir, and Telbivudine
lead to further improvement in the care of patients with
imminent hepatic decompensation [3,4]. Yet, with the
cumulative clinical experience using such NUCs, it became clear
that use of anti-viral agents may be associated with a number
of hepatic and extra hepatic undesirable adverse effects [5]. In
2006, Lange and co-workers reported the development of lactic
acidosis believed to be the consequence of mitochondrial toxicity,
observed in 5 out of 16 patients with cirrhosis and advanced
liver disease and a MELD score >20 treated with ETV [6]. The
authors consequently advised caution in administration of ETV
in patients with impaired liver functions. Furthermore, in 2011,
investigators from Hong-Kong reported a mortality rate of 19%
in ETV treated patients with acute exacerbation of HBV by week
48 as compared to only 4% in LAM treated historical controls [7].
This report added further concern regarding the safety of ETV in
patients with acute exacerbation of CHB or decompensated CLD.
To the best knowledge of this reviewer, prospectively controlled
trials testing speciﬁcally lactic acidosis during hepatic decompen-
sation in NUCs recipients are not available. Thus, the accurate risk
of lactic acidosis in ETV recipients with acute exacerbation or
decompensated CHB remains controversial and most probablyJournal of Hepatology 20
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Open access under CC BY-NC-ND license.low as also reﬂected in a letter from Italy, where 1 out of 6
patients with a high MELD score treated with ETV developed
lactic acidosis albeit in association with septicemia [8]. The short
and long-term risk/beneﬁt ratio in using NUCs in patients with
acute exacerbation/and or decompensated CHB is clearly in favor
of a beneﬁt [9,10]. Yet, although ETV has repeatedly been shown
to suppress HBV load more efﬁciently and with a much better
resistance proﬁle as compared to LAM, the cost of ETV is
signiﬁcantly higher. Moreover, AASLD (2009) and EASL (2012)
guidelines do not recommend a speciﬁc NUC for treatment of
decompensated CLD or acute exacerbation, although there is a
consensus regarding the importance of treatment with a potent
anti-viral agent. Consequently, LAM is still widely used in many
countries and especially in low resource regions. Recently,
Xiao-Guang Ye et al. from China conducted a meta-analysis of
12 randomized controlled Chinese and one English clinical trials
comparing treatment of LAM (N = 450) with ETV (N = 423) in
decompensated HBV cirrhosis [11]. One of the major conclusions
of this analysis was that despite the much better suppression of
viral load in ETV recipients, the mortality rate in LAM and ETV
recipients with decompensated cirrhosis was similar ranging
between 7.89% and 6.37% respectively. In this meta-analysis the
safety record for both anti-viral agents was similar. Thus,
although no data are provided on incidence of lactic acidosis,
and despite the fact that mortality rates were similar using either
agent, the authors practically ‘‘vindicate’’ and endorse the long-
term use of ETV which has a better resistance proﬁle and is more
effective in suppression of viral load in decompensated cirrhosis.
In the present issue of the journal Chen and co-workers from
Taiwan add their own experience in treating CHB patients with
severe acute exacerbation and hepatic decompensation with
LAM or ETV [12]. In this retrospective, non-randomized study,
215 and 107 patients were treated with ETV or LAM respectively.
The main result of this study using univariate analysis at week 24
of treatment suggest that LAM recipients had a higher rate of over-
all and liver related short-term (24 weeks) mortality (despite a
higher HBeAg loss) as compared to ETV. As expected, at week 24
of treatment, suppression of viral load was more effective in ETV
as compared to LAM recipients. However, after adjusting for base-
line factors, i.e., MELD score, ascites, and hepatic encephalopathy,
overall and liver related mortality were similar for both groups as
also reported in the recent meta-analysis from China [11]. The
choice between ETV and LAM was not an independent factor for14 vol. 60 j 1108–1109
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overall and liver relatedmortality in patientswith decompensated
CHB. A cut-off of a MELD score >24 was predictive for treatment
ineffectiveness and week 24 mortality suggesting referral for liver
transplantation.
As also acknowledged by the authors, the study has two major
limitations, namely the retrospective and the non-randomized
design. Consequently it appears that LAM recipients had more
advanced liver injury at baseline as compared to the ETV group.
Therefore, the strength of the conclusions and the implications
on routine clinical practice which can be drawn from the results
are limited. Regardless of this reservation, LAM can still be used
in countries where more advanced (and more costly) NUCs are
unavailable. Yet, available clinical evidence suggests that clini-
cians treating CHB patients with acute HBV exacerbation or
decompensated liver disease should use the most potent NUC
available to them. The study results provide further indirect evi-
dence regarding the safety of ETV in such patients. Yet, as already
suggested before, these patients require close follow-up and dose
adjustment of ETV when indicated.Conﬂict of interest
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